PARSIPPANY, N.J. / Jul 12, 2023 / Business Wire / Zoetis Inc. (NYSE:ZTS) has been named to Fast Company’s list of Best Workplaces for Innovators for 2023. Zoetis is the only stand-alone animal health company to be included on this year’s list which honors businesses that demonstrate a commitment to encouraging innovation at all levels.
“Our innovative culture means we are always seeking to understand how we can meet our customers’ next unmet need,” said Rob Polzer, Executive Vice President and President, Research & Development. “As the world leader in animal health, our scientists are exploring innovations across the continuum of animal healthcare - from prediction to prevention, detection and treatment – so we can help pets live longer, healthier lives and keep farm animals healthier and more productive.”
Driven by a purpose to nurture the world and humankind by advancing care for animals and underscored by a strong culture, several initiatives contributed to Zoetis being named to the list:
“Our innovative culture at Zoetis is supported by our core beliefs. In particular, “Run It Like You Own It” stands for accountability and ownership from each colleague,” said Evelyn Ortiz, Chief Talent, Diversity and Inclusion Officer at Zoetis. “As part of our commitment to our colleagues, we strive to create an environment where they feel valued and cared for, which fosters innovation and our colleagues’ best work.”
Developed in collaboration with Accenture, the 2023 Best Workplaces for Innovators ranks 100 winners from a variety of industries, including entertainment, biotech, consumer packaged goods, marketing, education, healthcare, and many more. Zoetis ranked 60th on this year’s list. Fast Company editors and Accenture researchers worked together to score nearly 1,000 submissions, and a panel of eight distinguished judges reviewed and endorsed the top 100 companies. The 2023 awards feature workplaces from around the world.
About Zoetis
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.1 billion in 2022 with approximately 13,800 employees. For more information, visit www.zoetis.com.
DISCLOSURE NOTICES
Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to: business plans or prospects; R&D commitments, goals and aspirations; and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov , www.zoetis.com , or on request from Zoetis.
Last Trade: | US$176.96 |
Daily Change: | 0.25 0.14 |
Daily Volume: | 1,754,854 |
Market Cap: | US$79.840B |
November 04, 2024 September 26, 2024 August 06, 2024 May 02, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB